Redeye comments on Oncopeptides Q3 report 2024. Revenues in Q3 increased slightly compared to Q2, but product sales declined. Nevertheless, sales should improve in the next quarters as the Spanish launch gains pace.
ANNONS
Redeye comments on Oncopeptides Q3 report 2024. Revenues in Q3 increased slightly compared to Q2, but product sales declined. Nevertheless, sales should improve in the next quarters as the Spanish launch gains pace.